Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Update

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a large decrease in short interest during the month of July. As of July 15th, there was short interest totaling 1,795 shares, a decrease of 31.6% from the June 30th total of 2,625 shares. Based on an average daily volume of 4,660 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Bavarian Nordic Trading Up 0.8%

Shares of OTCMKTS:BVNRY opened at $9.12 on Friday. The firm’s 50 day moving average is $9.32 and its two-hundred day moving average is $9.78. The firm has a market capitalization of $2.17 billion, a P/E ratio of 12.00 and a beta of 1.20. Bavarian Nordic has a 52 week low of $8.67 and a 52 week high of $13.00.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 9.32% and a net margin of 19.74%.The business had revenue of $165.70 million during the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.